Cataract Surgery Clinical Trial
Official title:
Intracameral Antibiotic Safety Study
The goal of this study is to determine the safety (but not efficacy in preventing infection) of sterile-packaged and pre-loaded injectable solutions of both vancomycin and moxifloxacin at certain dosages and concentrations as prepared by a compounding pharmacy when used intracamerally at the time of cataract surgery.
Use of injectable prophylactic intracameral antibiotics during cataract surgery is gaining popularity worldwide due to the growing body of scientific evidence supporting its use. To date, there is no sterile-packaged antibiotic that has FDA approval for this indication. Surgeons using intracameral injectable antibiotics during cataract surgery must use existing pharmaceuticals off-label and/or rely on imprecise and sub-sterile compounding pharmacies to dispense these types of medications. Both of these scenarios may pose significant risk to patient safety. Description of the Treatment: Approximately 0.2 mL of either pre-loaded sterile vancomycin hydrochloride 1% solution (1 mg/0.1 mL of normal saline) or moxifloxacin hydrochloride 0.15% solution (150 μg/0.1 mL of normal saline) is injected into the eye with a blunt tip 30 gauge cannula through a small clear corneal incision as the last step in the cataract removal procedure. The purpose of the treatment is for prophylaxis against post-operative infections and endophthalmitis. Description of Effector Pharmaceuticals/Drugs: Vancomycin is a hydrophilic glycopeptide antibiotic that has been well studied in many different forms: intravenous injectable, oral tablet and even topical eye drop solutions. It is derived from Actinobacteria spp. Moxifloxacin is a synthetic fourth generation fluoroquinolone and has, likewise, been available in many forms including intravenous injectable, oral tablet and topical eye drop solutions. In this study, a contracted compounding pharmacy will produce the two pharmaceutical agents at the concentration/dosage mentioned above under the USP 797 guidelines. Therapeutic Mode of Action: The primary mode of action for vancomycin is inhibition of cell wall synthesis in gram positive bacteria. The molecule forms hydrogen bonds with terminal amnio acid moieties of the N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) polymer. The disruption to the polymerization and cross-linking of NAM-NAG complexes undermines the structural integrity of the bacterial organism leading to bacteriostasis and eventually cell death. The primary mode of action for moxifloxacin is inhibiting DNA gyrases, both type II topoisomerase and topoisomerase IV. These enzymes are essential for bacterial DNA replication to occur. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02573610 -
Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery
|
Phase 3 | |
Completed |
NCT02910362 -
Intra-surgical Evaluation of CATS Tonometer Prism and Abbott Medical Optics Versus Alcon Phacoemulsification Machines
|
N/A | |
Recruiting |
NCT01193504 -
Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification
|
Phase 4 | |
Completed |
NCT01455233 -
2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery
|
Phase 4 | |
Completed |
NCT01199510 -
Efficacy Evaluation of SYSTANE® ULTRA in Patients Scheduled for Cataract Surgery
|
Phase 4 | |
Completed |
NCT04146961 -
The PanOptix Trifocal IOL: A Study of Patient Satisfaction, Visual Disturbances, and Uncorrected Visual Performance
|
||
Completed |
NCT00585975 -
Efficacy and Safety of Bromfenac Ophthalmic Solution
|
Phase 2 | |
Completed |
NCT00406913 -
Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery
|
N/A | |
Not yet recruiting |
NCT04131335 -
Use of Prophylactic Lubricating Drops After Cataract Surgery
|
N/A | |
Recruiting |
NCT05331690 -
Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN)
|
Phase 4 | |
Withdrawn |
NCT04563559 -
PREFERENTIAL Study
|
Phase 2/Phase 3 | |
Completed |
NCT04732351 -
Evaluation of the Active Sentry System During Cataract Surgery With the Centurion Phacoemulsifier
|
||
Completed |
NCT02128113 -
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
|
Phase 2 | |
Completed |
NCT03873454 -
The Effects of Music on Perioperative Outcomes in Cataract Surgery
|
N/A | |
Completed |
NCT04769856 -
Impact of Non-fasting on Anxiety in Cataract Surgery
|
N/A | |
Withdrawn |
NCT00604305 -
Comperative Trial Between an Accommodative Iol and Monofocal Iol
|
N/A | |
Completed |
NCT05925894 -
Efficacy Mydrane ® for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma.
|
N/A | |
Not yet recruiting |
NCT06136780 -
Impact of Free Reading Glasses on Work and Visual Function Following Cataract Surgery in Honduras
|
N/A | |
Completed |
NCT04633954 -
Brimonidine for Subconjunctival Hemorrhage From Femtosecond Laser Assisted Cataract Surgery
|
N/A | |
Completed |
NCT03644875 -
Study of Etacoat in Patients With Cataract Surgery Via the Anterior Chamber
|